Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35
Maxim Group analyst Michael Okunewitch initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $35.
Stocks · News reference
8-K filing — KYNTRA BIO, INC. (KYNB)
Filed: 2026-10-06 AccNo: 0001193125-26-415545 Size: 150 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Kyntra Bio announced the appointment of Andrew E. Singer, an experienced biotechnology finance executive with 25+ years in investment banking and corporate strategy, to its Board of Directors as an independent director and Audit Committee member effective October 1, 2026. Simultaneously, Maykin Ho stepped down after nearly eight years of service. Singer's appointment is expected to strengthen the company's financial position as it advances its rare disease and oncology pipeline.
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.